Education
About Us
Working with TipRanks
Follow Us
Atossa Therapeutics (GB:0HJ7)
LSE:0HJ7
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.05Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: ―
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with notable reductions in operating costs and promising clinical advancements for (Z)-endoxifen, particularly in metastatic breast cancer. However, the financial impact of a write-off and decreased interest income offset some of these positives.Company Guidance
In their recent earnings call, Atossa Therapeutics provided guidance highlighting several key metrics. Operating expenses for 2024 decreased to $27.6 million, down from $31.4 million in 2023, due to disciplined spending in R&D and G&A. R&D expenses fell by $3.2 million to $14.1 million, driven by a $2.6 million reduction in spending on (Z)-endoxifen trials. G&A expenses decreased slightly to $13.5 million, with a $1.9 million reduction in compensation costs. The company reported a net loss of $25.5 million or $0.20 per share, compared to $30.1 million or $0.24 per share in the previous year. Atossa closed the year with $71.1 million in cash and cash equivalents, providing a strong financial position to advance their lead program, (Z)-endoxifen, particularly in metastatic breast cancer settings. Additionally, a Phase I study demonstrated a clinical benefit rate of approximately 26% in patients with previous progression on multiple therapies, and a related Phase II study suggested nearly a five-month improvement in progression-free survival for certain subgroups. The company plans to focus on the U.S. FDA process for a streamlined path to market, with further guidance expected as they engage with key opinion leaders and regulatory authorities.Reduced Operating Expenses
Total operating expenses for the year were $27.6 million, down from $31.4 million in 2023, a decrease of $3.8 million, reflecting disciplined spending in both R&D and G&A.
R&D Cost Reduction
R&D expenses declined by $3.2 million from $17.3 million in 2023 to $14.1 million in 2024, driven by a reduction in clinical and preclinical spending on (Z)-endoxifen trials and drug development.
Strong Cash Position
The company closed the year with $71.1 million in cash and cash equivalents, providing a healthy runway to advance (Z)-endoxifen and other research initiatives.
(Z)-endoxifen Clinical Progress
(Z)-endoxifen showed promising results in Phase I and Phase II studies, demonstrating robust plasma concentration, a 26% clinical benefit rate in difficult-to-treat settings, and significant reduction in mammographic breast density.
Metastatic Breast Cancer Focus
The company is prioritizing the advancement of (Z)-endoxifen in metastatic breast cancer, aiming for a potential expedited approval and faster time to market.
GB:0HJ7 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0HJ7 Earnings-Related Price Changes
No data currently available
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Atossa Therapeutics (GB:0HJ7) report earnings?
Atossa Therapeutics (GB:0HJ7) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is Atossa Therapeutics (GB:0HJ7) earnings time?
Atossa Therapeutics (GB:0HJ7) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Atossa Therapeutics stock?
The P/E ratio of Atossa Therapeutics is N/A.
What is GB:0HJ7 EPS forecast?
GB:0HJ7 EPS forecast for the fiscal quarter 2025 (Q2) is -0.06.